Earnings · China A-shares
Chongqing Genrix Biopharmaceutical Co., Ltd. Class A (688443) earnings
Chongqing Genrix Biopharmaceutical Co., Ltd. Class A published its Q3 report on 2026-10-30: net profit +98.08% year on year, +94.84% excluding one-off items. Wave Radar's earnings-quality score is 59 of 100 (Questionable). The stock moved +16.30% in the 3 trading days after the report.
- Report
- Q3 report
- Published
- 2026-10-30
- Period end
- 2026-09-30
- Net profit YoY
- +98.08%
- Excl. one-offs YoY
- +94.84%
- Result
- Bad / loss
- Quality score
- 59
- Quality
- Questionable
Stock move after the report
Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.
| After | Return | vs index |
|---|---|---|
| 1 day | +11.72% | — |
| 3 days | +16.30% | — |
| 7 days | +13.36% | — |
| 14 days | +0.95% | — |
Report history
Over the last 8 reports, net profit grew year on year in 6 of them. The stock rose in the 3 trading days after 3 of 6 reports (average +3.48%).
| Report | Published | Net profit | Profit YoY | Excl. one-offs YoY | Revenue YoY | EPS | ROE | 3 days after | 30 days after | 30d vs index |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 Q3 report | 2026-10-31 | -¥6.38M | +98.08% | +94.84% | +274.75% | -0.02 | -0.40% | +16.30% | — | — |
| 2026 interim report | 2026-08-31 | -¥316.16M | -9.29% | -2.04% | +237.29% | -0.86 | -22.14% | -4.67% | -4.71% | +4.63% |
| 2026 Q1 report | 2026-04-30 | -¥149.40M | -23.76% | -6.18% | +233.63% | -0.41 | -9.89% | -2.18% | -29.64% | -31.69% |
| 2025 annual report | 2026-04-30 | -¥535.65M | +32.81% | +28.06% | +666.66% | -1.46 | -28.90% | -2.18% | -29.64% | -31.69% |
| 2025 Q3 report | 2025-10-31 | -¥332.59M | +39.12% | +32.78% | +1562.05% | -0.91 | -17.01% | +0.00% | -7.85% | -3.16% |
| 2025 interim report | 2025-08-30 | -¥289.29M | +20.07% | +12.91% | +358429.65% | -0.79 | -14.62% | +6.75% | -12.30% | -13.14% |
| 2025 Q1 report | 2025-04-26 | -¥120.72M | +26.29% | +11.95% | +318303.78% | -0.33 | -5.85% | +4.71% | +14.91% | +11.67% |
| 2024 annual report | 2025-04-26 | -¥797.27M | +0.50% | +1.06% | +2384.10% | -2.17 | -32.65% | +4.71% | +14.91% | +11.67% |
The last 8 reports. Net profit is attributable to shareholders and year-to-date (a Q3 report covers the first nine months). Moves count trading days from the first tradeable session after publication; "30d vs index" is the excess return over CSI 300.
How to read this
Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.